Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marla Shapiro

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
The Pediatric Infectious Disease Journal|September 15, 2016
Is It Time for Vaccination to "Go Viral"?Roy K Philip, Marla Shapiro, Pauline Paterson, et al.
Lancet (London, England)|May 18, 2024
Totality of evidence refutes neoplasm risk with fezolinetantGenevieve Neal-Perry, Nanette Santoro, Antonio Cano, et al.
Sexual Medicine|December 18, 2022
Response to Commentary by SpielmansJames A Simon, Anita H Clayton, Irwin Goldstein, et al.
Sexual Medicine|November 18, 2022
Effects of Flibanserin on Subdomain Scores of the Female Sexual Function Index in Women With Hypoactive Sexual Desire DisorderJames A Simon, Anita H Clayton, Irwin Goldstein, et al.
Family Medicine|September 29, 2021
A Master Class in Family Doctor Leadership: Evaluating an Innovative ProgramDavid White, June C Carroll, Sara Crann, et al.
Maturitas|January 14, 2025
Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapyMarla Shapiro C M, Xi Wu, Xuegong Wang, et al.
Maturitas|November 19, 2025
Early onset, maintenance of effect, and day-/night-time findings following fezolinetant treatment for moderate to severe vasomotor symptoms associated with menopause: A pooled phase 3 analysisMarla Shapiro C M, Genevieve Neal-Perry, Petra Stute, et al.
Menopause (New York, N.Y.)|June 3, 2015
NAMS supports judicious use of systemic hormone therapy for women aged 65 years and olderMargery L S Gass, Pauline M Maki, Jan L Shifren, et al.
Lancet (London, England)|March 16, 2023
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled studySamuel Lederman, Faith D Ottery, Antonio Cano, et al.
Maturitas|May 15, 2024
Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopauseMarla Shapiro C M, Antonio Cano, Rossella E Nappi, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
The Pediatric Infectious Disease Journal|September 15, 2016
Is It Time for Vaccination to "Go Viral"?Roy K Philip, Marla Shapiro, Pauline Paterson, et al.
Lancet (London, England)|May 18, 2024
Totality of evidence refutes neoplasm risk with fezolinetantGenevieve Neal-Perry, Nanette Santoro, Antonio Cano, et al.
Sexual Medicine|December 18, 2022
Response to Commentary by SpielmansJames A Simon, Anita H Clayton, Irwin Goldstein, et al.
Sexual Medicine|November 18, 2022
Effects of Flibanserin on Subdomain Scores of the Female Sexual Function Index in Women With Hypoactive Sexual Desire DisorderJames A Simon, Anita H Clayton, Irwin Goldstein, et al.
Family Medicine|September 29, 2021
A Master Class in Family Doctor Leadership: Evaluating an Innovative ProgramDavid White, June C Carroll, Sara Crann, et al.
Maturitas|January 14, 2025
Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapyMarla Shapiro C M, Xi Wu, Xuegong Wang, et al.
Maturitas|November 19, 2025
Early onset, maintenance of effect, and day-/night-time findings following fezolinetant treatment for moderate to severe vasomotor symptoms associated with menopause: A pooled phase 3 analysisMarla Shapiro C M, Genevieve Neal-Perry, Petra Stute, et al.
Menopause (New York, N.Y.)|June 3, 2015
NAMS supports judicious use of systemic hormone therapy for women aged 65 years and olderMargery L S Gass, Pauline M Maki, Jan L Shifren, et al.
Lancet (London, England)|March 16, 2023
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled studySamuel Lederman, Faith D Ottery, Antonio Cano, et al.
Maturitas|May 15, 2024
Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopauseMarla Shapiro C M, Antonio Cano, Rossella E Nappi, et al.
Pageof 3